QQQ   292.38 (+0.73%)
AAPL   142.94 (-0.04%)
MSFT   245.01 (+0.95%)
META   148.06 (+0.68%)
GOOGL   97.64 (+0.72%)
AMZN   102.97 (+2.41%)
TSLA   171.96 (+3.18%)
NVDA   194.52 (+1.51%)
NIO   12.31 (+2.41%)
BABA   111.77 (+0.51%)
AMD   74.00 (+2.14%)
T   20.30 (+0.69%)
MU   59.87 (-2.98%)
F   13.39 (+3.88%)
CGC   2.92 (+2.82%)
GE   80.60 (-0.28%)
DIS   108.07 (+0.45%)
AMC   5.14 (+2.59%)
PFE   43.56 (+0.02%)
PYPL   80.23 (+0.74%)
NFLX   352.37 (-0.21%)
QQQ   292.38 (+0.73%)
AAPL   142.94 (-0.04%)
MSFT   245.01 (+0.95%)
META   148.06 (+0.68%)
GOOGL   97.64 (+0.72%)
AMZN   102.97 (+2.41%)
TSLA   171.96 (+3.18%)
NVDA   194.52 (+1.51%)
NIO   12.31 (+2.41%)
BABA   111.77 (+0.51%)
AMD   74.00 (+2.14%)
T   20.30 (+0.69%)
MU   59.87 (-2.98%)
F   13.39 (+3.88%)
CGC   2.92 (+2.82%)
GE   80.60 (-0.28%)
DIS   108.07 (+0.45%)
AMC   5.14 (+2.59%)
PFE   43.56 (+0.02%)
PYPL   80.23 (+0.74%)
NFLX   352.37 (-0.21%)
QQQ   292.38 (+0.73%)
AAPL   142.94 (-0.04%)
MSFT   245.01 (+0.95%)
META   148.06 (+0.68%)
GOOGL   97.64 (+0.72%)
AMZN   102.97 (+2.41%)
TSLA   171.96 (+3.18%)
NVDA   194.52 (+1.51%)
NIO   12.31 (+2.41%)
BABA   111.77 (+0.51%)
AMD   74.00 (+2.14%)
T   20.30 (+0.69%)
MU   59.87 (-2.98%)
F   13.39 (+3.88%)
CGC   2.92 (+2.82%)
GE   80.60 (-0.28%)
DIS   108.07 (+0.45%)
AMC   5.14 (+2.59%)
PFE   43.56 (+0.02%)
PYPL   80.23 (+0.74%)
NFLX   352.37 (-0.21%)
QQQ   292.38 (+0.73%)
AAPL   142.94 (-0.04%)
MSFT   245.01 (+0.95%)
META   148.06 (+0.68%)
GOOGL   97.64 (+0.72%)
AMZN   102.97 (+2.41%)
TSLA   171.96 (+3.18%)
NVDA   194.52 (+1.51%)
NIO   12.31 (+2.41%)
BABA   111.77 (+0.51%)
AMD   74.00 (+2.14%)
T   20.30 (+0.69%)
MU   59.87 (-2.98%)
F   13.39 (+3.88%)
CGC   2.92 (+2.82%)
GE   80.60 (-0.28%)
DIS   108.07 (+0.45%)
AMC   5.14 (+2.59%)
PFE   43.56 (+0.02%)
PYPL   80.23 (+0.74%)
NFLX   352.37 (-0.21%)
NASDAQ:GTHX

G1 Therapeutics - GTHX Stock Forecast, Price & News

$7.84
+0.41 (+5.52%)
(As of 01/31/2023 10:57 AM ET)
Add
Compare
Today's Range
$7.45
$7.85
50-Day Range
$5.13
$6.85
52-Week Range
$3.84
$17.49
Volume
477,609 shs
Average Volume
959,445 shs
Market Capitalization
$336.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.25

G1 Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
263.4% Upside
$27.00 Price Target
Short Interest
Bearish
7.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
0.58mentions of G1 Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$204,976 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.46) to ($2.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

164th out of 1,055 stocks

Pharmaceutical Preparations Industry

73rd out of 518 stocks


GTHX stock logo

About G1 Therapeutics (NASDAQ:GTHX) Stock

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Stock News Headlines

G1 Therapeutics (NASDAQ:GTHX) Upgraded at JPMorgan Chase & Co.
Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Company Calendar

Last Earnings
11/02/2022
Today
1/31/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+298.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-148,350,000.00
Net Margins
-328.58%
Pretax Margin
-325.45%

Debt

Sales & Book Value

Annual Sales
$31.48 million
Book Value
$3.38 per share

Miscellaneous

Free Float
39,440,000
Market Cap
$336.41 million
Optionable
Optionable
Beta
1.64

Key Executives

  • Mr. John E. Bailey Jr. (Age 58)
    CEO, Pres & Director
    Comp: $1.04M
  • Ms. Jennifer K. Moses CPA (Age 48)
    Chief Financial Officer
    Comp: $606.27k
  • Dr. Mark A. Velleca M.D.Dr. Mark A. Velleca M.D. (Age 59)
    Ph.D., Sr. Advisor & Director
    Comp: $242.69k
  • Dr. Rajesh K. Malik Ch.B. (Age 64)
    M.B., M.D., Chief Medical Officer and Sr. VP of R&D
    Comp: $596.37k
  • Mr. Mark Avagliano (Age 47)
    Chief Bus. Officer
    Comp: $606.05k
  • Mr. Andrew Perry (Age 50)
    Chief Commercial Officer
    Comp: $568.6k
  • Mr. Terry L. Murdock (Age 63)
    Chief Operating Officer
  • Mr. Alexander D. Smith M.S.
    VP of Technical Operations
  • Dr. Jay C. Strum Ph.D. (Age 59)
    Chief Scientific Officer
  • Mr. William C. Roberts (Age 54)
    VP of Investor Relations & Corp. Communications













GTHX Stock - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GTHX shares.
View GTHX analyst ratings
or view top-rated stocks.

What is G1 Therapeutics' stock price forecast for 2023?

6 Wall Street research analysts have issued 12-month price targets for G1 Therapeutics' shares. Their GTHX share price forecasts range from $10.00 to $35.00. On average, they predict the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 263.4% from the stock's current price.
View analysts price targets for GTHX
or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2023?

G1 Therapeutics' stock was trading at $5.43 at the beginning of 2023. Since then, GTHX stock has increased by 36.8% and is now trading at $7.43.
View the best growth stocks for 2023 here
.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,090,000 shares, an increase of 20.2% from the December 31st total of 2,570,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 2.7 days.
View G1 Therapeutics' Short Interest
.

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our GTHX earnings forecast
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.05. The firm earned $23.58 million during the quarter, compared to analysts' expectations of $22.64 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 172.97% and a negative net margin of 328.58%.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends
.

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $7.43.

How much money does G1 Therapeutics make?

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $318.84 million and generates $46.85 million in revenue each year. The company earns $-148,350,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

How many employees does G1 Therapeutics have?

The company employs 148 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.

This page (NASDAQ:GTHX) was last updated on 1/31/2023 by MarketBeat.com Staff